Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection

Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang Hyub Han, Seung Up Kim

Research output: Contribution to journalArticle

Abstract

Background/Aims It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. Methods 428 patients with recurrent HCC after curative resection who were treated with TACE were enrolled. Results The median age of the study population was 59.2 years. On multivariate analysis, 2 TACE procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxyprothrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P<0.05). In addition, 2 and 3 TACE procedures within 6 months independently predicted mortality in the entire study population (HR = 1.863 and 1.620, respectively). The probability of progression to BCLC stage C in patients with BCLC stage 0-B HCC and the mortality rate in the entire study population were significantly higher in patients treated with 2 TACE within 6 months than in those who underwent fewer procedures (P = 0.002 and P<0.001, respectively). Conclusions More than 2 TACE procedures within 6 months might be associated with the refractoriness to TACE in patients with recurrent HCC after curative resection.

Original languageEnglish
Article numbere0214613
JournalPloS one
Volume14
Issue number4
DOIs
Publication statusPublished - 2019 Apr

Fingerprint

resection
hepatoma
Liver
Hepatocellular Carcinoma
liver neoplasms
Hazards
Liver Neoplasms
Refractory materials
Population
Mortality
multivariate analysis
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

@article{08acc34fbb084db4899e4f040c8bcb4e,
title = "Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection",
abstract = "Background/Aims It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. Methods 428 patients with recurrent HCC after curative resection who were treated with TACE were enrolled. Results The median age of the study population was 59.2 years. On multivariate analysis, 2 TACE procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxyprothrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P<0.05). In addition, 2 and 3 TACE procedures within 6 months independently predicted mortality in the entire study population (HR = 1.863 and 1.620, respectively). The probability of progression to BCLC stage C in patients with BCLC stage 0-B HCC and the mortality rate in the entire study population were significantly higher in patients treated with 2 TACE within 6 months than in those who underwent fewer procedures (P = 0.002 and P<0.001, respectively). Conclusions More than 2 TACE procedures within 6 months might be associated with the refractoriness to TACE in patients with recurrent HCC after curative resection.",
author = "Jeon, {Mi Young} and Kim, {Hye Soo} and Lim, {Tae Seop} and Han, {Dai Hoon} and Kim, {Beom Kyung} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Choi, {Gi Hong} and Choi, {Jin Sub} and Han, {Kwang Hyub} and Kim, {Seung Up}",
year = "2019",
month = "4",
doi = "10.1371/journal.pone.0214613",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. / Jeon, Mi Young; Kim, Hye Soo; Lim, Tae Seop; Han, Dai Hoon; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Choi, Gi Hong; Choi, Jin Sub; Han, Kwang Hyub; Kim, Seung Up.

In: PloS one, Vol. 14, No. 4, e0214613, 04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection

AU - Jeon, Mi Young

AU - Kim, Hye Soo

AU - Lim, Tae Seop

AU - Han, Dai Hoon

AU - Kim, Beom Kyung

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Choi, Gi Hong

AU - Choi, Jin Sub

AU - Han, Kwang Hyub

AU - Kim, Seung Up

PY - 2019/4

Y1 - 2019/4

N2 - Background/Aims It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. Methods 428 patients with recurrent HCC after curative resection who were treated with TACE were enrolled. Results The median age of the study population was 59.2 years. On multivariate analysis, 2 TACE procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxyprothrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P<0.05). In addition, 2 and 3 TACE procedures within 6 months independently predicted mortality in the entire study population (HR = 1.863 and 1.620, respectively). The probability of progression to BCLC stage C in patients with BCLC stage 0-B HCC and the mortality rate in the entire study population were significantly higher in patients treated with 2 TACE within 6 months than in those who underwent fewer procedures (P = 0.002 and P<0.001, respectively). Conclusions More than 2 TACE procedures within 6 months might be associated with the refractoriness to TACE in patients with recurrent HCC after curative resection.

AB - Background/Aims It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. Methods 428 patients with recurrent HCC after curative resection who were treated with TACE were enrolled. Results The median age of the study population was 59.2 years. On multivariate analysis, 2 TACE procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxyprothrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P<0.05). In addition, 2 and 3 TACE procedures within 6 months independently predicted mortality in the entire study population (HR = 1.863 and 1.620, respectively). The probability of progression to BCLC stage C in patients with BCLC stage 0-B HCC and the mortality rate in the entire study population were significantly higher in patients treated with 2 TACE within 6 months than in those who underwent fewer procedures (P = 0.002 and P<0.001, respectively). Conclusions More than 2 TACE procedures within 6 months might be associated with the refractoriness to TACE in patients with recurrent HCC after curative resection.

UR - http://www.scopus.com/inward/record.url?scp=85063938794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063938794&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0214613

DO - 10.1371/journal.pone.0214613

M3 - Article

C2 - 30947275

AN - SCOPUS:85063938794

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0214613

ER -